IntraGel Therapeutics
PrivateLast Round
Strategic
Aug 20, 2026
Total Funding Raised
$12.45M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
IntraGel Therapeutics is a biotechnology company that develops a proprietary gel-based drug delivery platform, SRGel, for the localized and sustained release of anti-cancer medications in solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IntraGel Therapeutics Comparables
Compare IntraGel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TargTex | 84% | |
| Gordian Pharma Ltd. | 82% | |
| Double Bond Pharmaceutical International AB | 81% |
IntraGel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Aug 20, 2026 | ||||
| Seed | Aug 3, 2023 | ||||
| Pre Seed | May 1, 2023 | ||||
| Accelerator | Jul 21, 2022 | ||||
| Seed | Aug 1, 2021 |
IntraGel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Innovation Authority | Pre Seed, Seed |
| Next Generation Technology (NGT3VC) | Seed |
| MassChallenge Israel | Accelerator |
| NGT HealthCare II | Pre Seed, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 481% MoM, reaching 1.4K.
- Aug 20, 2026
$7M round led by UroGen Pharma Ltd.
Recent news
Latest coverage and updates
- partners_withAug 20, 2026
Intragel Therapeutics Ltd. and UroGen Pharma, Inc. partner in Israel on Aug 20th '26 through collaboration and investment agreements under which UroGen Pharma, Inc. invests up to $7 million, gains access to the SRGel platform, and receives exclusive options for worldwide rights to TumoCure and up to three additional oncology products.
- receives_financingAug 20, 2026
On Aug 20th '26, Intragel Therapeutics Ltd. receives up to $7M in equity financing from UroGen to support the Phase 2 clinical study of TumoCure for advanced head and neck cancer in Israel.
IntraGel Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about IntraGel Therapeutics's valuation, stock price, and market status.
Is IntraGel Therapeutics a public or private company?
IntraGel Therapeutics is a private company.
What is the current stock price of IntraGel Therapeutics?
IntraGel Therapeutics is a private company, so its shares have no public market price. Caplight tracks IntraGel Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IntraGel Therapeutics worth (valuation)?
Valuation information for IntraGel Therapeutics is not publicly available.
Can I buy IntraGel Therapeutics stock?
IntraGel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IntraGel Therapeutics's last funding round?
IntraGel Therapeutics's most recent funding round was Strategic on August 20, 2026.
Who are the main investors in IntraGel Therapeutics?
Key investors in IntraGel Therapeutics include Next Generation Technology (NGT3VC).
Will IntraGel Therapeutics IPO soon?
No public IPO plans have been announced for IntraGel Therapeutics.
How can I track IntraGel Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in IntraGel Therapeutics's shares on secondary markets.